Literature DB >> 22503792

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Isabel Fofana1,2, Samira Fafi-Kremer1,2,3, Patric Carolla1,2, Catherine Fauvelle1,2, Muhammad Nauman Zahid1,2, Marine Turek1,2, Laura Heydmann1,2, Karine Cury1,2, Juliette Hayer4, Christophe Combet4, François-Loïc Cosset5, Thomas Pietschmann6, Marie-Sophie Hiet7, Ralf Bartenschlager7, François Habersetzer1,2,8, Michel Doffoël1,2,8, Zhen-Yong Keck9, Steven K H Foung9, Mirjam B Zeisel1,2, Françoise Stoll-Keller1,2,3, Thomas F Baumert1,2,8.   

Abstract

BACKGROUND & AIMS: The development of vaccines and other strategies to prevent hepatitis C virus (HCV) infection is limited by rapid viral evasion. HCV entry is the first step of infection; this process involves several viral and host factors and is targeted by host-neutralizing responses. Although the roles of host factors in HCV entry have been well characterized, their involvement in evasion of immune responses is poorly understood. We used acute infection of liver graft as a model to investigate the molecular mechanisms of viral evasion.
METHODS: We studied factors that contribute to evasion of host immune responses using patient-derived antibodies, HCV pseudoparticles, and cell culture-derived HCV that express viral envelopes from patients who have undergone liver transplantation. These viruses were used to infect hepatoma cell lines that express different levels of HCV entry factors.
RESULTS: By using reverse genetic analyses, we identified altered use of host-cell entry factors as a mechanism by which HCV evades host immune responses. Mutations that alter use of the CD81 receptor also allowed the virus to escape neutralizing antibodies. Kinetic studies showed that these mutations affect virus-antibody interactions during postbinding steps of the HCV entry process. Functional studies with a large panel of patient-derived antibodies showed that this mechanism mediates viral escape, leading to persistent infection in general.
CONCLUSIONS: We identified a mechanism by which HCV evades host immune responses, in which use of cell entry factors evolves with escape from neutralizing antibodies. These findings advance our understanding of the pathogenesis of HCV infection and might be used to develop antiviral strategies and vaccines.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503792      PMCID: PMC5295797          DOI: 10.1053/j.gastro.2012.04.006

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  39 in total

Review 1.  Viral hepatitis.

Authors:  Harvey Alter
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

2.  A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.

Authors:  Heidi E Drummer; Irene Boo; Anne L Maerz; Pantelis Poumbourios
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  A new standard of care for the treatment of chronic HCV infection.

Authors:  Wolf Peter Hofmann; Stefan Zeuzem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-05       Impact factor: 46.802

5.  The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Authors:  George Koutsoudakis; Eva Herrmann; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 6.  Hepatitis C virus entry and neutralization.

Authors:  Zania Stamataki; Joe Grove; Peter Balfe; Jane A McKeating
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

7.  Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.

Authors:  Kimberly A Dowd; Dale M Netski; Xiao-Hong Wang; Andrea L Cox; Stuart C Ray
Journal:  Gastroenterology       Date:  2009-03-17       Impact factor: 22.682

8.  Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness.

Authors:  Luke Uebelhoer; Jin-Hwan Han; Benoit Callendret; Guaniri Mateu; Naglaa H Shoukry; Holly L Hanson; Charles M Rice; Christopher M Walker; Arash Grakoui
Journal:  PLoS Pathog       Date:  2008-09-05       Impact factor: 6.823

9.  Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response.

Authors:  Eva Dazert; Christoph Neumann-Haefelin; Stéphane Bressanelli; Karen Fitzmaurice; Julia Kort; Jörg Timm; Susan McKiernan; Dermot Kelleher; Norbert Gruener; John E Tavis; Hugo R Rosen; Jaqueline Shaw; Paul Bowness; Hubert E Blum; Paul Klenerman; Ralf Bartenschlager; Robert Thimme
Journal:  J Clin Invest       Date:  2009-01-12       Impact factor: 14.808

10.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.

Authors:  Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-28       Impact factor: 11.205

View more
  44 in total

1.  Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Authors:  Chaturaka Rodrigo; Melanie R Walker; Preston Leung; Auda A Eltahla; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Sunita Dwivedi; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Infect Genet Evol       Date:  2017-01-05       Impact factor: 3.342

2.  Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Authors:  Brian G Pierce; Zhen-Yong Keck; Patrick Lau; Catherine Fauvelle; Ragul Gowthaman; Thomas F Baumert; Thomas R Fuerst; Roy A Mariuzza; Steven K H Foung
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-26       Impact factor: 11.205

3.  A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry.

Authors:  Catherine Fauvelle; Melanie Lambotin; Laura Heydmann; Ekambaranellore Prakash; Sunil Bhaskaran; Mohan Vishwaraman; Thomas F Baumert; Christiane Moog
Journal:  Hepatol Int       Date:  2017-07-11       Impact factor: 6.047

4.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

Review 5.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

6.  Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure.

Authors:  Masahiro Kajihara; Eri Nakayama; Andrea Marzi; Manabu Igarashi; Heinz Feldmann; Ayato Takada
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

7.  Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.

Authors:  R T Chung; F D Gordon; M P Curry; T D Schiano; S Emre; K Corey; J F Markmann; M Hertl; J J Pomposelli; E A Pomfret; S Florman; M Schilsky; T J Broering; R W Finberg; G Szabo; P D Zamore; U Khettry; G J Babcock; D M Ambrosino; B Leav; M Leney; H L Smith; D C Molrine
Journal:  Am J Transplant       Date:  2013-01-28       Impact factor: 8.086

Review 8.  Viral evasion and challenges of hepatitis C virus vaccine development.

Authors:  Brian G Pierce; Zhen-Yong Keck; Steven Kh Foung
Journal:  Curr Opin Virol       Date:  2016-09-19       Impact factor: 7.090

9.  Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells.

Authors:  Vedashree Ramakrishnaiah; Christine Thumann; Isabel Fofana; Francois Habersetzer; Qiuwei Pan; Petra E de Ruiter; Rob Willemsen; Jeroen A A Demmers; Victor Stalin Raj; Guido Jenster; Jaap Kwekkeboom; Hugo W Tilanus; Bart L Haagmans; Thomas F Baumert; Luc J W van der Laan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

10.  Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.

Authors:  Valentina D'Arienzo; Alain Moreau; Louis D'Alteroche; Valérie Gissot; Emmanuelle Blanchard; Catherine Gaudy-Graffin; Emmanuelle Roch; Frédéric Dubois; Bruno Giraudeau; Jean-Christophe Plantier; Alain Goudeau; Philippe Roingeard; Denys Brand
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.